此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Placental Cells for Diabetic Foot Ulcers

2026年6月30日 更新者:Wake Forest University Health Sciences

Phase 1 Safety Trial of Placental Stem Cells (PLSC) to Accelerate the Healing of Diabetic Foot Ulcers

The purpose of this research study is to test the safety of placental stem cells to treat non-healing diabetic foot ulcers.

研究概览

地位

尚未招聘

详细说明

This is a prospective, non-randomized, single institution, Phase 1 safety trial to evaluate the safety of placental stem cells and the rate of diabetic foot ulcer healing in a population of subjects with non-healing diabetic foot ulcers for at least 4 weeks. The trial will also explore the clinical outcomes of placental stem cells treatment on diabetic peripheral neuropathy. Furthermore, the trial will evaluate the effect of the placental stem cells on serum biomarkers associated with diabetic foot ulcers and diabetic peripheral neuropathy (measured pre- and post-treatment) and correlate the biomarker levels with any changes in diabetic foot ulcers and diabetic peripheral neuropathy. Twelve adult subjects with non-healing diabetic foot ulcers for at least four weeks from diagnosis and not more than 12 months with wound sizes ≥ 2 cm2 and ≤ 4 cm2 will be recruited and treated. Subjects will be followed for 12 months after treatment.

研究类型

介入性

注册 (估计的)

12

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • North Carolina
      • Winston-Salem、North Carolina、美国、27157

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Diagnosed with Type 2 Diabetes mellitus (DM) - for at least 1 year
  • Unilateral non-healing Diabetic Foot Ulcer (DFU) > 2 cm2 and ≤ 4 cm2 (length × width) for at least four weeks despite Atrium Health Wake Forest Baptist standard of care treatment (which can include total contact cast, knee high air cast, and/or compression wrap)
  • No new diabetes medication for at least 2 weeks pre-treatment
  • Subjects must be willing to avoid steroids for the week prior to procedure day

Exclusion Criteria:

  • Clinical signs of active infection requiring systemic antibiotic therapy less than 7 days prior to enrollment.
  • Radiographic or clinical evidence of active and untreated osteomyelitis at the target ulcer site. Current use of systemic immunosuppressive therapy, including chronic corticosteroids (equivalent to >10 mg/day prednisone for >14 days).
  • Hemoglobin (Hgb) A1C >12.0 at screening or time in range for the blood glucose level (TIR) less than 30%. Hb A1c should not be used for patient with hypoalbuminemia or anemia in the past 3 months and for patients with Chronic Kidney disease stage 4. For patients who have Continuous Glucose Monitor (CGM), instead of Hb A1c, TIR (time in range) less than 30 % will be used.
  • Patients who are unable / unwilling to tolerate an effective offloading approach. This includes total contact cast, soft felted cast or knee high fracture boot.
  • Current alcohol or substance abuse that, in the opinion of the investigators, would interfere with study participation.
  • Active malignancy or malignancy related limb amputation.
  • Women that are pregnant or planning to become pregnant during the study.
  • Patients with albumin levels less than 3.5 or prealbumin levels less than 18.
  • Subjects with any conditions that the clinical Investigator believes may jeopardize the safety of the patient to participate in the trial.
  • Severe peripheral arterial disease (PAD) (Ankle-Brachial Index (ABI) less than 0.5) or TCOM (Transcutaneous Oximetry Measurement) less than 40 mmHg.
  • TWSB > 30 cm2 (total wound surface burden)

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Diabetic with Foot Ulcer
Type 2 diabetes mellitus with a non-healing (> 4 weeks) unilateral diabetic foot ulcer despite standard of care treatment
Injection of 30 M placenta stem cells into/around the diabetic foot ulcer and along the anterior and posterior tibial arteries of the index leg.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Number of Injection Sites Bleeding
大体时间:Month 1
Number of Injection Sites Bleeding
Month 1
Number of Injection Sites Bleeding
大体时间:Month 3
Number of Injection Sites Bleeding
Month 3
Number of Injection Sites Bleeding
大体时间:Month 6
Number of Injection Sites Bleeding
Month 6
Number of Injection Sites Bleeding
大体时间:Month 12
Number of Injection Sites Bleeding
Month 12
Number of Injection Sites infection/inflammation
大体时间:Month 1
Number of Injection Sites infection/inflammation
Month 1
Number of Injection Sites infection/inflammation
大体时间:Month 3
Number of Injection Sites infection/inflammation
Month 3
Number of Injection Sites infection/inflammation
大体时间:Month 6
Number of Injection Sites infection/inflammation
Month 6
Number of Injection Sites infection/inflammation
大体时间:Month 12
Number of Injection Sites infection/inflammation
Month 12
Number of Injection Sites with damage to surrounding tissue
大体时间:Month 1
Number of Injection Sites with damage to surrounding tissue
Month 1
Number of Injection Sites with damage to surrounding tissue
大体时间:Month 3
Number of Injection Sites with damage to surrounding tissue
Month 3
Number of Injection Sites with damage to surrounding tissue
大体时间:Month 6
Number of Injection Sites with damage to surrounding tissue
Month 6
Number of Injection Sites with damage to surrounding tissue
大体时间:Month 12
Number of Injection Sites with damage to surrounding tissue
Month 12
Number of Subjects with pain
大体时间:Month 1
Number of Subjects with pain
Month 1
Number of Subjects with pain
大体时间:Month 3
Number of Subjects with pain
Month 3
Number of Subjects with pain
大体时间:Month 6
Number of Subjects with pain
Month 6
Number of Subjects with pain
大体时间:Month 12
Number of Subjects with pain
Month 12
Number of Subjects with allergic reaction to placental cells
大体时间:Month 1
Number of Subjects with allergic reaction to placental cells
Month 1
Number of Subjects with allergic reaction to placental cells
大体时间:Month 3
Number of Subjects with allergic reaction to placental cells
Month 3
Number of Subjects with allergic reaction to placental cells
大体时间:Month 6
Number of Subjects with allergic reaction to placental cells
Month 6
Number of Subjects with allergic reaction to placental cells
大体时间:Month 12
Number of Subjects with allergic reaction to placental cells
Month 12
Number of Subjects with worsening of wound
大体时间:Month 1
Number of Subjects with worsening of wound
Month 1
Number of Subjects with worsening of wound
大体时间:Month 3
Number of Subjects with worsening of wound
Month 3
Number of Subjects with worsening of wound
大体时间:Month 6
Number of Subjects with worsening of wound
Month 6
Number of Subjects with worsening of wound
大体时间:Month 12
Number of Subjects with worsening of wound
Month 12

次要结果测量

结果测量
措施说明
大体时间
Diabetic Foot Ulcer (DFU) size
大体时间:Month 12
DFU healing in this trial will be assessed by measuring the size of the DFU and plotting open wound size over the 12-month follow-up period.
Month 12

其他结果措施

结果测量
措施说明
大体时间
Change in Diabetic Peripheral Neuropathy - Semmes-Weinstein Monofilament and Vibration Test
大体时间:Months 1, 3, 6 and 12
The Semmes-Weinstein Monofilament Test is a diagnostic tool used to assess cutaneous touch and pressure sensation. By using calibrated nylon strands that buckle at specific forces, clinicians can evaluate peripheral nerve function and reliably detect the loss of protective sensation, primarily caused by conditions like diabetic neuropathy
Months 1, 3, 6 and 12

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Lucian G. Vlad, MD、Atrium Health Wake Forest Baptist

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年10月1日

初级完成 (估计的)

2028年12月1日

研究完成 (估计的)

2028年12月1日

研究注册日期

首次提交

2026年6月30日

首先提交符合 QC 标准的

2026年6月30日

首次发布 (实际的)

2026年7月7日

研究记录更新

最后更新发布 (实际的)

2026年7月7日

上次提交的符合 QC 标准的更新

2026年6月30日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅